Antonio M GottoJr

Antonio M GottoJr

Auto-generated profile, based on publicly available information

Antonio M GottoJr

Weill Medical College, Cornell University, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2021 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
HPHenry Pownall
Henry Pownall
CRCorina Rosales
Corina Rosales
BGBaiba Gillard
Baiba Gillard
AGAntonio M. Gotto
Antonio M. Gotto

24 January 2014 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
JFJean-Charles Fruchart
Jean-Charles Fruchart
JDJean Davignon
Jean Davignon
MHMichel P. Hermans
Michel P. Hermans
KAKhalid Al-Rubeaan
Khalid Al-Rubeaan
PAPierre Amarenco
Pierre Amarenco
PZPaul Zimmet
Paul Zimmet
Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of obesity, metabolic syndrome and type 2 diabetes. While best standards of care, including high-dose statins, can ameliorate the risk of vascular complications, patients remain at high risk of cardiovascular events. The Residual Risk Reduction Initiative (R3i) has previously highlighted atherogenic dyslipidaemia, defined as the imbalance between proatherogenic triglyceride-rich apolipoprotein B-containing-lipoproteins and antiatherogenic apolipoprotein A-I-lipoproteins (as in high-density lipoprotein, HDL), as an important modifiable contributor to lipid-related residual cardiovascular risk, especially in insulin-resistant conditions. As part of its mission to improve awareness and clinical management of atherogenic dyslipidaemia, the R3i has identified three key priorities for action: i) to improve recognition of atherogenic dyslipidaemia in patients at high cardiometabolic risk with or without diabetes; ii) to improve implementation and adherence to guideline-based therapies; and iii) to improve therapeutic strategies for managing atherogenic dyslipidaemia. The R3i believes that monitoring of non-HDL cholesterol provides a simple, practical tool for treatment decisions regarding the management of lipid-related residual cardiovascular risk. Addition of a fibrate, niacin (North and South America), omega-3 fatty acids or ezetimibe are all options for combination with a statin to further reduce non-HDL cholesterol, although lacking in hard evidence for cardiovascular outcome benefits. Several emerging treatments may offer promise. These include the next generation peroxisome proliferator-activated receptorα agonists, cholesteryl ester transfer protein inhibitors and monoclonal antibody therapy targeting proprotein convertase subtilisin/kexin type 9. However, long-term outcomes and safety data are clearly needed. In conclusion, the R3i believes that ongoing trials with these novel treatments may help to define the optimal management of atherogenic dyslipidaemia to reduce the clinical and socioeconomic burden of residual cardiovascular risk.

1 January 2014 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AGAntonio M. Gotto
Antonio M. Gotto
CCChristopher P. Cannon
Christopher P. Cannon
XLXiujiang Susie Li
Xiujiang Susie Li
SVSanskruti Vaidya
Sanskruti Vaidya
UKUma Kher
Uma Kher
PBPhilip Barter
Philip Barter

14 April 2014 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
AGAntonio M. Gotto
Antonio M. Gotto
UKUma Kher
Uma Kher
MCManash Shankar Chatterjee
Manash Shankar Chatterjee
YLYang Liu
Yang Liu
XLXiujiang Susie Li
Xiujiang Susie Li
TIthe DEFINE Investigators
the DEFINE Investigators
Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that has previously been shown to reduce low-density lipoprotein cholesterol (LDL-C) and raise high-density lipoprotein cholesterol (HDL-C) in patients with or at high risk of coronary heart disease in the 76-week, placebo-controlled, Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib (DEFINE) trial. Here, we report the results of the 2-year extension to the DEFINE study where patients (n = 803) continued on the same assigned treatment as in the original 76-week study. Treatment with anacetrapib during the 2-year extension was well tolerated with a safety profile similar to patients on placebo. No clinically important abnormalities in liver enzymes, blood pressure, electrolytes, or adverse experiences were observed during the extension. At the end of the extension study, relative to the original baseline value, anacetrapib reduced Friedewald-calculated LDL-C by 39.9% and increased HDL-C by 153.3%, compared to placebo. The apparent steady state mean plasma trough concentration of anacetrapib was ∼640 nmol/L. Geometric mean plasma concentrations of anacetrapib did not appear to increase beyond week 40 of the 2-year extension of the 76-week DEFINE base study. In conclusion, an additional 2 years of treatment with anacetrapib were well tolerated with durable lipid-modifying effects on LDL-C and HDL-C.

13 March 2022 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
ULUlrich Laufs
Ulrich Laufs
CBChristie M. Ballantyne
Christie M. Ballantyne
Maciej BanachMaciej Banach
Maciej Banach
HBHarold Bays
Harold Bays
Alberico Luigi Catapano‌Alberico Luigi Catapano‌
Alberico Luigi Catapano‌
GMG B John Mancini
G B John Mancini
Despite the high incidence of patients with statin tolerance problems, randomized evaluations of nonstatin oral treatment options for lowering of low-density lipoprotein cholesterol (LDL-C) in this population are sparse. To assess the LDL-C lowering effect of bempedoic acid in patients not taking statins. This was a pooled analysis of data from patients enrolled in four phase 3 bempedoic acid studies (12 to 52 weeks in duration) who were not taking concomitant statins (Phase 3 No Statin Cohort) and a phase 3 bempedoic acid plus ezetimibe fixed-dose combination study (BA+EZE FDC No Statin Cohort). The primary endpoint for all studies was the percent change from baseline to week 12 in LDL-C levels. Safety and tolerability were assessed by laboratory values and adverse events. In the Phase 3 No Statin Cohort, bempedoic acid (n = 394) lowered LDL-C levels at week 12 significantly more than placebo (n = 192; -26.5% [95% CI, -29.7%, -23.2%]; P<0.001). The fixed-dose combination of bempedoic acid with ezetimibe lowered LDL-C by 39.2% (95% CI, -51.7% to -26.7%; P<0.001). Muscle-related disorders occurred at a rate of 26.4 and 28.6 per 100 person-years with bempedoic acid and placebo, respectively. In patients with hypercholesterolemia unable to take statins, bempedoic acid lowered LDL-C levels by a mean of 26.5% vs placebo and bempedoic acid + ezetimibe fixed-dose combination lowered LDL-C by 39.2%. The treatments were generally well tolerated, suggesting that bempedoic acid may be efficacious and well tolerated in this challenging-to-treat patient population.

1 March 2019 in The American Journal of Pathology
Verified
Journal Article
Closed access
MWMatthew F Wipperman
Matthew F Wipperman
DMDavid C. Montrose
David C. Montrose
AGAntonio M. Gotto
Antonio M. Gotto
DHDavid P. Hajjar
David P. Hajjar